Consun Pharmaceutical Group Ltd. (1681) AI Stock Analysis

• Market Cap: HK$12.57B
• Dividend Yield: 4.15%
• Average Volume (3M): 3.22M
• Price to Earnings (P/E): 11.8
• Beta (1Y): 0.51
• Revenue Growth: 19.05%
• EPS Growth: 13.68%
• Country: HK
• Employees: 3,164
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.63
• Shares Outstanding: 847,973,400
• 10 Day Avg. Volume: 2,130,627
• 30 Day Avg. Volume: 3,216,320
• PEG Ratio: 0.52
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 2.12
• P/FCF Ratio: 6.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$20.33
• Price Target Upside: 31.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 67 Neutral
• Price Target: HK$16.50 ▲(6.93% Upside)

Consun Pharmaceutical Group Ltd. demonstrates strong financial performance with robust revenue growth and profitability. However, technical indicators suggest weak market momentum, which could pose short-term challenges. The stock's valuation appears attractive with a low P/E ratio and a solid dividend yield, making it appealing for value and income investors. The absence of recent earnings call data and corporate events limits the analysis, but the overall outlook remains moderately positive.

Positive Factors

Revenue Growth

The consistent revenue growth indicates a strong market position and effective product demand, supporting long-term business sustainability.

Profitability Margins

High and improving profitability margins reflect efficient cost management and strong pricing power, enhancing long-term financial health.

Balance Sheet Health

Improved leverage indicates better financial stability and reduced risk, providing a solid foundation for future growth and investment.

Negative Factors

Cash Flow Data Limitations

Lack of recent cash flow data limits the ability to assess cash generation efficiency, potentially obscuring financial health insights.

Cash Utilization

Underutilized cash reserves could indicate missed opportunities for growth or shareholder returns, affecting long-term strategic positioning.

Growth Sustainability

Rapid growth rates can be difficult to sustain, potentially leading to future volatility in performance and strategic adjustments.

Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model

Company Description

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

How the Company Makes Money

Consun Pharmaceutical Group Ltd. generates revenue through the sale of its pharmaceutical products, primarily focusing on modern Chinese medicines and medical contrast medium products. The company's key revenue streams include the domestic market in China, where it distributes its products through a network of distributors and direct sales to hospitals and pharmacies. Consun leverages its research and development capabilities to enhance its product offerings and maintain a competitive edge in the market. The company may also engage in strategic partnerships, licensing agreements, and collaborations to expand its product reach and enhance its market position, although specific details on partnerships are not provided.

Consun Pharmaceutical Group Ltd. Financial Statement Overview

Summary

Consun Pharmaceutical Group Ltd. exhibits strong financial health with robust revenue growth and profitability margins. The balance sheet indicates a stable financial position with decreasing leverage and increasing equity. However, the cash flow analysis is limited by missing recent data, making it difficult to fully assess cash generation efficiency.

Income Statement

Consun Pharmaceutical Group Ltd. has demonstrated strong growth in revenue, consistently increasing from 2019 to 2024. The company shows impressive profitability with a gross profit margin consistently above 75% and a net profit margin improving from 4.6% in 2019 to 30.7% in 2024. EBIT and EBITDA margins have also shown positive trends, indicating effective cost management. However, the high growth rate may pose sustainability challenges in future periods.

Balance Sheet

The company maintains a robust balance sheet with a strong equity position and increasing total assets. The debt-to-equity ratio has improved, reflecting reduced leverage over the years. The return on equity has also improved significantly, indicating efficient use of equity capital. Nonetheless, high cash reserves might suggest underutilization of funds, which could be optimized for growth or shareholder returns.

Cash Flow

Consun Pharmaceutical Group Ltd. has maintained positive free cash flow consistently, although recent data is unavailable for comprehensive analysis. The company has shown the ability to generate cash from operations, but the lack of recent cash flow data limits a full assessment. Historical trends suggest sound cash flow management, but recent growth in free cash flow percentages are needed for a clearer picture.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.97B	2.59B	2.34B	2.04B	1.75B
Gross Profit	2.24B	1.92B	1.76B	1.53B	1.32B
EBITDA	1.05B	963.06M	785.89M	728.71M	618.79M
Net Income	910.46M	784.53M	682.91M	590.17M	498.79M
Balance Sheet
Total Assets	5.85B	5.51B	4.89B	4.36B	3.95B
Cash, Cash Equivalents and Short-Term Investments	3.87B	3.58B	3.04B	2.43B	1.94B
Total Debt	267.17M	511.53M	460.18M	610.97M	549.41M
Total Liabilities	1.46B	1.59B	1.45B	1.45B	1.43B
Stockholders Equity	4.10B	3.63B	3.15B	2.62B	2.22B
Cash Flow
Free Cash Flow	977.99M	766.41M	896.09M	627.29M	818.36M
Operating Cash Flow	1.09B	818.97M	947.68M	725.54M	867.06M
Investing Cash Flow	-186.91M	-231.77M	-368.80M	-298.31M	-25.70M
Financing Cash Flow	-729.26M	-280.10M	-342.20M	-166.66M	-279.80M

Consun Pharmaceutical Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.43
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Negative. The current price of 15.43 is below the 20-day moving average (MA) of 16.09, below the 50-day MA of 15.49, and above the 200-day MA of 10.98, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 43.69 is Neutral, neither overbought nor oversold. The STOCH value of 22.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1681.

Consun Pharmaceutical Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	―	HK$6.47B	7.25	10.85%	5.90%	-20.64%	-25.39%
0719	―	HK$10.01B	10.82	7.48%	4.14%	1.65%	-16.38%
1681	―	HK$12.57B	11.76	25.92%	4.15%	19.05%	13.68%
0570	―	$13.04B	197.41	-1.26%	3.28%	-9.58%	-128.83%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0460	―	$13.62B	―	-1.87%	0.77%	19.21%	-115.91%

Consun Pharmaceutical Group Ltd. Corporate Events

Consun Pharmaceutical Group Redesignates Professor Zhu Quan as Non-Executive Director

Consun Pharmaceutical Group Ltd. announced the redesignation of Professor Zhu Quan from an executive director to a non-executive director, effective September 25, 2025. This change allows Professor Zhu to focus more on other commitments while continuing to contribute to the company’s research and development efforts. The redesignation is part of the company’s ongoing efforts to optimize its leadership structure and maintain its competitive edge in the pharmaceutical industry.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group Announces Board Composition and Committee Roles

Consun Pharmaceutical Group Ltd. has announced the composition of its board of directors and the roles of each member. The board includes executive, non-executive, and independent non-executive directors, and has established four committees: Audit, Remuneration, Nomination, and Environmental, Social and Governance. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and stakeholder engagement.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Reports Strong Interim Financial Results for 2025

Consun Pharmaceutical Group Ltd. reported a significant financial growth for the first half of 2025, with revenue increasing by 23.7% to RMB1,568,588,000 and profit attributable to equity shareholders rising by 24.6% to RMB498,299,000 compared to the same period in 2024. This strong performance is reflected in the declared interim dividend of HKD0.33 per share, indicating a positive outlook for stakeholders and reinforcing the company’s robust market positioning.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group Announces Upcoming Board Meeting to Discuss Interim Results

Consun Pharmaceutical Group Ltd. has scheduled a board meeting for August 19, 2025, to discuss and approve the unaudited consolidated interim results for the first half of the year, consider the announcement of these results, and deliberate on the potential payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial health and strategic decisions, potentially impacting its market positioning and shareholder value.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group Engages in Significant Wealth Management Subscriptions

Consun Pharmaceutical Group Ltd. has announced that its subsidiaries have subscribed to wealth management products from SPD Bank and its subsidiary, SPDB Wealth Management, with a total principal amount of RMB875,500,000. These transactions, funded by the company’s idle funds, are considered discloseable under Hong Kong’s Listing Rules due to their aggregated value exceeding certain percentage thresholds, though they do not require shareholder approval.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.